Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

Triple negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study is to explore the clinical relevance of Lehmann TNBC subtypes by identifying any differences in response to neoa...

Descripción completa

Detalles Bibliográficos
Autores: Santonja, Angela, Albanell Mestres, Joan, Alba, Emilio
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2018
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/41927
Acceso en línea:http://hdl.handle.net/10230/41927
http://dx.doi.org/10.18632/oncotarget.25413
Access Level:acceso abierto
Palabra clave:Carboplatin
Neoadjuvant therapy
Pathologic complete response
Subtyping
Triple negative breast cancer
id ES_5fad9882aed54ea7c06e1a091aeab7df
oai_identifier_str oai:recercat.cat:10230/41927
network_acronym_str ES
network_name_str España
repository_id_str
spelling Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapySantonja, AngelaAlbanell Mestres, JoanAlba, EmilioCarboplatinNeoadjuvant therapyPathologic complete responseSubtypingTriple negative breast cancerTriple negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study is to explore the clinical relevance of Lehmann TNBC subtypes by identifying any differences in response to neoadjuvant chemotherapy among them. We determined Lehmann subtypes by gene expression profiling in paraffined pre-treatment tumor biopsies from 125 TNBC patients treated with neoadjuvant anthracyclines and/or taxanes +/- carboplatin. We explored the clinicopathological characteristics of Lehmann subtypes and their association with the pathologic complete response (pCR) to different treatments. The global pCR rate was 37%, and it was unevenly distributed within Lehmann's subtypes. Basal-like 1 (BL1) tumors exhibited the highest pCR to carboplatin containing regimens (80% vs 23%, p=0.027) and were the most proliferative (Ki-67>50% of 88.2% vs. 63.7%, p=0.02). Luminal-androgen receptor (LAR) patients achieved the lowest pCR to all treatments (14.3% vs 42.7%, p=0.045 when excluding mesenchymal stem-like (MSL) samples) and were the group with the lowest proliferation (Ki-67≤50% of 71% vs 27%, p=0.002). In our cohort, only tumors with LAR phenotype presented non-basal-like intrinsic subtypes (HER2-enriched and luminal A). TNBC patients present tumors with a high genetic diversity ranging from highly proliferative tumors, likely responsive to platinum-based therapies, to a subset of chemoresistant tumors with low proliferation and luminal characteristics.This work was supported by Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) from Instituto de Salud Carlos III (ISCIII) (CB16/12/00241, CB16/12/00471, CB16/12/00481) and by research grants from ISCIII (PI13/00730), Mutua Madrileña 2013 and Sociedad Española de Oncología Médica (SEOM) 2013. The authors acknowledge support through grant TIN2017-88728-C2-1-R from MICINN-SPAIN. Angela Santonja has a predoctoral grant PFIS-ISCIII (FI12/00489).Impact Journal201920192018info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/41927http://dx.doi.org/10.18632/oncotarget.25413reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)Inglésinfo:eu-repo/grantAgreement/ES/2PE/TIN2017-88728-C2-1-RCopyright : © 2018 Santonja et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), https://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.https://creativecommons.org/licenses/by/3.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/419272026-05-29T05:05:01Z
dc.title.none.fl_str_mv Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
title Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
spellingShingle Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
Santonja, Angela
Carboplatin
Neoadjuvant therapy
Pathologic complete response
Subtyping
Triple negative breast cancer
title_short Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
title_full Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
title_fullStr Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
title_full_unstemmed Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
title_sort Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
dc.creator.none.fl_str_mv Santonja, Angela
Albanell Mestres, Joan
Alba, Emilio
author Santonja, Angela
author_facet Santonja, Angela
Albanell Mestres, Joan
Alba, Emilio
author_role author
author2 Albanell Mestres, Joan
Alba, Emilio
author2_role author
author
dc.subject.none.fl_str_mv Carboplatin
Neoadjuvant therapy
Pathologic complete response
Subtyping
Triple negative breast cancer
topic Carboplatin
Neoadjuvant therapy
Pathologic complete response
Subtyping
Triple negative breast cancer
description Triple negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study is to explore the clinical relevance of Lehmann TNBC subtypes by identifying any differences in response to neoadjuvant chemotherapy among them. We determined Lehmann subtypes by gene expression profiling in paraffined pre-treatment tumor biopsies from 125 TNBC patients treated with neoadjuvant anthracyclines and/or taxanes +/- carboplatin. We explored the clinicopathological characteristics of Lehmann subtypes and their association with the pathologic complete response (pCR) to different treatments. The global pCR rate was 37%, and it was unevenly distributed within Lehmann's subtypes. Basal-like 1 (BL1) tumors exhibited the highest pCR to carboplatin containing regimens (80% vs 23%, p=0.027) and were the most proliferative (Ki-67>50% of 88.2% vs. 63.7%, p=0.02). Luminal-androgen receptor (LAR) patients achieved the lowest pCR to all treatments (14.3% vs 42.7%, p=0.045 when excluding mesenchymal stem-like (MSL) samples) and were the group with the lowest proliferation (Ki-67≤50% of 71% vs 27%, p=0.002). In our cohort, only tumors with LAR phenotype presented non-basal-like intrinsic subtypes (HER2-enriched and luminal A). TNBC patients present tumors with a high genetic diversity ranging from highly proliferative tumors, likely responsive to platinum-based therapies, to a subset of chemoresistant tumors with low proliferation and luminal characteristics.
publishDate 2018
dc.date.none.fl_str_mv 2018
2019
2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/41927
http://dx.doi.org/10.18632/oncotarget.25413
url http://hdl.handle.net/10230/41927
http://dx.doi.org/10.18632/oncotarget.25413
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv info:eu-repo/grantAgreement/ES/2PE/TIN2017-88728-C2-1-R
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by/3.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/3.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Impact Journal
publisher.none.fl_str_mv Impact Journal
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409224916729856
score 15,81155

Similares en LA Referencia